Email this page: News Release

Medivation Announces Positive New Efficacy Data From Phase 1-2 Trial of MDV3100 in Advanced Prostate Cancer Patients

To (email address):   Separate multiple addresses with commas. Maximum 200 characters.
Your name:
Your email address:   Copy yourself These email addresses will be used to email the page on your behalf and will not be used by Medivation, Inc. for any marketing purposes.
Add a comment:
Send:    Full page    Link to page
Type in number:
This helps Medivation, Inc. prevent automated submissions.